We are live on ! Find out more

1,781 hedge funds and large institutions have $145B invested in Pfizer in 2014 Q1 according to their latest regulatory filings, with 117 funds opening new positions, 733 increasing their positions, 747 reducing their positions, and 55 closing their positions.

New
Increased
Maintained
Reduced
Closed

113% more first-time investments, than exits

New positions opened: 117 | Existing positions closed: 55

110% more call options, than puts

Call options by funds: $1.89B | Put options by funds: $900M

10% more funds holding in top 10

Funds holding in top 10: 250274 (+24)

3% more funds holding

Funds holding: 1,7371,781 (+44)

5% more capital invested

Capital invested by funds: $138B → $145B (+$6.46B)

0.72% more ownership

Funds ownership: 73.18%73.9% (+0.72%)

2% less repeat investments, than reductions

Existing positions increased: 733 | Existing positions reduced: 747

Holders
1,781
Holders Change
+44
Holders Change %
+2.53%
% of All Funds
51.41%
Holding in Top 10
274
Holding in Top 10 Change
+24
Holding in Top 10 Change %
+9.6%
% of All Funds
7.91%
New
117
Increased
733
Reduced
747
Closed
55
Calls
$1.89B
Puts
$900M
Net Calls
+$990M
Net Calls Change
+$946M
Name Holding Trade Value Shares
Change
Change in
Stake
TH
326
TCTC Holdings
Texas
$33.3M -$110K -3,689 -0.3%
PI
327
PineBridge Investments
New York
$33.1M -$9.61M -322,177 -23%
JAM
328
Jupiter Asset Management
United Kingdom
$33M -$57.3K -1,921 -0.2%
MAM
329
Martingale Asset Management
Massachusetts
$32.6M +$4.86M +162,900 +18%
GAM
330
Gotham Asset Management
New York
$32.6M +$24.9M +835,325 +357%
SMDAM
331
Sumitomo Mitsui DS Asset Management
Japan
$32.5M -$2.26M -75,758 -7%
VFAM
332
Valley Forge Asset Management
Pennsylvania
$32.4M -$340K -11,395 -1%
Alyeska Investment Group
333
Alyeska Investment Group
Illinois
$32.3M +$31.6M +1,059,867 New
SAC
334
Smith Affiliated Capital
New York
$32.1M
Mackenzie Financial
335
Mackenzie Financial
Ontario, Canada
$31.7M +$8.58M +287,745 +38%
B
336
BP
United Kingdom
$31.2M -$3.14M -105,400 -9%
BPBT
337
Boston Private Bank & Trust
Massachusetts
$30.6M -$719K -24,103 -2%
Daiwa Securities Group
338
Daiwa Securities Group
Japan
$29.7M +$12.5M +418,543 +75%
CIM
339
Confluence Investment Management
Missouri
$29.7M +$2.16M +72,312 +8%
CC
340
Curian Capital
Colorado
$29.6M +$13.8M +463,816 +91%
Connor, Clark & Lunn Investment Management (CC&L)
341
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$29.5M -$2.79M -93,595 -10%
CC
342
Chubb Corp
New Jersey
$29.5M
SIM
343
Sadoff Investment Management
Wisconsin
$29.3M +$229K +7,694 +0.8%
ABI
344
Abrams Bison Investments
Maryland
$28.9M
MNA
345
Manning & Napier Advisors
New York
$28.9M -$4.03M -135,073 -12%
Brown Advisory
346
Brown Advisory
Maryland
$28.6M -$45.8M -1,535,001 -62%
B
347
Baird
Wisconsin
$28.6M +$456K +15,300 +2%
Tudor Investment Corp
348
Tudor Investment Corp
Connecticut
$28.1M +$26M +873,506 +1,792%
MMH
349
Menora Mivtachim Holdings
Israel
$27.9M -$1.88M -63,149 -6%
ISL
350
Ingalls & Snyder LLC
New York
$27.9M -$459K -15,379 -2%

PFE Hedge Fund Activity: Q1 2014 in Review

1,781 of the 3,464 institutional investors tracked by Wall St. Rank reported a position in Pfizer (PFE) for Q1 2014, worth a combined $145B — up 4.7% from $138B a quarter earlier.

Buyers outnumbered sellers: 117 funds opened new PFE positions and 55 closed out — a net gain of 62 holders — while 733 added to existing stakes and 747 trimmed.

The largest buyer was BlackRock Fund Advisors, adding an estimated $301M. The largest seller was Grantham, Mayo, Van Otterloo & Co (GMO), cutting an estimated $630M.

  • 1,781 institutional investors held Pfizer (PFE) as of Q1 2014, up from 1,737 in Q4 2013.
  • Funds reported $145B of Pfizer stock for Q1 2014, up 4.7% quarter-over-quarter.
  • 117 funds opened new Pfizer positions in Q1 2014 and 55 closed out, a net change of +62 holders.
  • The largest Pfizer buyer in Q1 2014 was BlackRock Fund Advisors, an estimated $301M added.
  • The largest Pfizer seller in Q1 2014 was Grantham, Mayo, Van Otterloo & Co (GMO), an estimated $630M sold.

Based on aggregated 13F filings for Q1 2014.